As the number of antibacterial medicines in the pipeline remains low, we anonymously surveyed pharmaceutical industry professionals on challenges and solutions for clinical development of these agents. Challenges were reported primarily as financial and regulatory. For multidrug-resistant organisms, there are needs for rapid diagnostic tests, new regulatory guidance, and adaptation of endpoints/trial designs. Regulators and public/private initiatives are addressing these challenges to help ensure that proposed solutions have the support of all involved stakeholders.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468719PMC
http://dx.doi.org/10.1128/AAC.00638-15DOI Listing

Publication Analysis

Top Keywords

challenges solutions
8
solutions clinical
8
clinical development
8
pharmaceutical industry
8
industry professionals
8
challenges
4
development antibacterial
4
antibacterial agents
4
agents survey
4
survey pharmaceutical
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!